August 29, 2016
Pharmacosmos has hired Chris Olsen DVM, as sales and technical
support for Uniferon® 200 mg/mL (Iron(III) Dextran)
throughout the United States.
Based near Des Moines, IA, Dr. Olsen will help veterinarians and
large commercial swine operations with the prevention and treatment
of sub-clinical and full-scale iron deficiency anemia in baby pigs
through injectable supplementation of Uniferon® 200
mg/mL. Duties will include further deployment and training for the
Uniferon® Farm Anemia Certification and Training
(F.A.C.T) program, whereby production managers and swine
veterinarians have access to convenient pen-side diagnostic tools
and knowledge that eliminate guesswork commonly associated with
detection of iron deficiency anemia.
Chris will also serve as the primary liaison to university swine
programs, state and national swine associations, spearhead field
trials and research, and present relevant research and updates at
major swine events.
Olsen is a recent graduate of the College of Veterinary
Medicine, Iowa State University, in Ames, IA and already has a wide
breadth of experience designing and conducting research trials.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.